Application No Internatio PCT/EP2005/001874

_		
A CLASSIE	ICATION OF SUBJECT	MATTER
	00311141575	~ AC1V20/22
1PC 7	C07K14/575	A61K38/22

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, WPI Data, PAJ

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х,ү	KRSTENANSKY J L ET AL: "NPY AND PYY ANALOGS AS ANTISECRETORY AGENTS" 1992, SMITH, J. A. AND J. E. RIVIER (ED.). PEPTIDES: CHEMISTRY AND BIOLOGY; TWELFTH AMERICAN PEPTIDE SYMPOSIUM, CAMBRIDGE, MASSACHUSETTS, USA, JUNE 16-21, 1991. LVIII+989P. ESCOM SCIENCE PUBLISHERS B.V.: LEIDEN, NETHERLANDS. ILLUS, PAGE(S) 136-137, XP002306038 ISSN: 90-72199-12-X the whole document/	1-19, 22-27, 31,37, 39,40, 42,45, 46,50, 51,55-75

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
<ul> <li>Special categories of cited documents:</li> <li>"A" document defining the general state of the art which is not considered to be of particular relevance</li> <li>"E" earlier document but published on or after the international filing date</li> </ul>	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "P" document published prior to the international filing date but later than the priority date claimed	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  "8" document member of the same patent family		
Date of the actual completion of the international search  23 June 2005	Date of mailing of the international search report  2 7 -09 2005		
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer  Groenendijk, M		

Internation Application No
PCT/EP2005/001874

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Х,Ү	WO 03/026591 A (BATTERHAM RACHEL LOUISE; GHATEI MOHAMMAD ALI (GB); IMP COLLEGE INNOVA) 3 April 2003 (2003-04-03)  The whole document; see especially pages	1-19, 22-27, 31,37, 39,40, 42,45, 46,50, 51,55-75
	41,42,49-57,63-70	
Х,Ү	KIRBY D A ET AL: "Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass." JOURNAL OF MEDICINAL CHEMISTRY. 27 OCT 1995, vol. 38, no. 22, 27 October 1995 (1995-10-27), pages 4579-4586, XP002306036 ISSN: 0022-2623	1-19, 22-27, 31,37, 39,40, 42,45, 46,50, 51,55-75
	See particularly page 4583, column 1	
X,Y	KIRBY D A ET AL: "Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues."  JOURNAL OF MEDICINAL CHEMISTRY. 5 FEB 1993, vol. 36, no. 3, 5 February 1993 (1993-02-05), pages 385-393, XP002333099 ISSN: 0022-2623 See particularly Table I	1-19, 22-27, 31,37, 39,40, 42,45, 46,50, 51,55-75
A	MICHEL M C ET AL: "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors."  PHARMACOLOGICAL REVIEWS. MAR 1998, vol. 50, no. 1, March 1998 (1998-03), pages 143-150, XP002306037 ISSN: 0031-6997 See particularly Table 1	
	•	
-	•	
		·

International application No.
T/EP2005/001874

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 63-72 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
23-26 (all complete); 1-19, 22, 27, 31, 36-40, 42, 45, 46, 50, 51, 55-75
Remark on Protest  The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 23-26(all complete);1-19,22,27,31,36-40,42,45,46, 50,51,55-75

Peptides according to claim 1 or 3 having a disulfide bridge or having two crosslinkable protected Cys amino acid substitutions, their preparation and use.

2. claims: 29,30,32-35(all complete);1-19,22,27,31,36-40,42,45,46, 50,51,55-75

Peptides according to claim 1 or 3 having a rigid bend involving positions corresponding to residues 9 and 10 in SEQ ID No. 2, their preparation and use.

3. claims: 1-19,22,27,31,36-40,42,45,46,50,51,55-75

Peptides according to claim 1 or 3 having at least one stabilizing amide bond between amino acid side chains, their preparation and use.

4. claims: 20,21(all complete);1-19,22,27,31,36-40,42,45,46, 50,51,55-75

Peptides according to claim 1 or 3 having a branched amino acid sequence resulting in 2 free N-terminal amino acids, their preparation and use.

5. claims: 47-49,52-54(all complete);1-19,22,27,31,36-40,42,45,46, 50,51,55-75

Peptides according to claim 1 or 3 having an N-terminal or C-terminal addition of a net basic amino acid sequence, their preparation and use.

6. claims: 28,44(all complete);1-19,22,31,36-40,42,45,46,50, 51,55-75

Peptides according to claim 1 or 3 having a deletion of amino acid residues 1-5 of SEQ ID No.2, their preparation and use.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. claims: 41(all complete);1-19,22,27,36-39,42,43,45,46, 50,51,55-75

Peptides according to claim 1 or 3 having a deletion of any of amino acid residues 8-15 of SEQ ID No.2, their preparation and use.

8. claims: 1-19,22,27,31,37,39,40,42,45,46,50,51,55-75

Peptides according to claim 1 or 3 having a deletion of amino acid residues 6 and 7 of SEQ ID No.2, their preparation and use.

9. claims: 1-19,22,27,31,36-40,43,45,46,50,51,55-75

Peptides according to claim 1 or 3 having a deletion of amino acid residues 16-19 of SEQ ID No.2, their preparation and use.

10. claims: 3-19,22,27,31,36-40,42,43,45,46,50,51,55-75

Peptides according to claim 3 as far as not covered by any of the previous subjects, their preparation and use.

PCT/EP2005/001874

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03026591 A	03-04-2003	BR 0212985 A CA 2461345 A1 CN 1596119 A EP 1499277 A2 JP 2005508324 T	30-08-2005 03-04-2003 16-03-2005 26-01-2005 31-03-2005